Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

[1]  G. Litjens,et al.  Deep learning in histopathology: the path to the clinic , 2021, Nature Medicine.

[2]  H. Aerts,et al.  Artificial intelligence for clinical oncology. , 2021, Cancer cell.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Andreas Holzinger,et al.  Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading , 2020, Communications Medicine.

[6]  Ellery Wulczyn,et al.  Interpretable survival prediction for colorectal cancer using deep learning , 2020, npj Digital Medicine.

[7]  Yingli Tian,et al.  Self-Supervised Visual Feature Learning With Deep Neural Networks: A Survey , 2019, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[8]  B. Mirjalili,et al.  Cancer Treatment by Caryophyllaceae-Type Cyclopeptides , 2021, Frontiers in Endocrinology.

[9]  R. Socher,et al.  Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains , 2020, Nature Communications.

[10]  Po-Hsuan Cameron Chen,et al.  Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens , 2020, JAMA oncology.

[11]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[12]  Lauren Wilcox,et al.  A Human-Centered Evaluation of a Deep Learning System Deployed in Clinics for the Detection of Diabetic Retinopathy , 2020, CHI.

[13]  Kaiming He,et al.  Improved Baselines with Momentum Contrastive Learning , 2020, ArXiv.

[14]  D. Ho.  Artificial intelligence in cancer therapy , 2020, Science.

[15]  Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. , 2020, JCO oncology practice.

[16]  B. van Ginneken,et al.  Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. , 2020, The Lancet. Oncology.

[17]  Ross B. Girshick,et al.  Momentum Contrast for Unsupervised Visual Representation Learning , 2019, 2020 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR).

[18]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20–49 Years , 2019, Journal of the National Cancer Institute.

[19]  M. Cooperberg,et al.  Genomic biomarkers in prostate cancer , 2018, Translational andrology and urology.

[20]  H. Sandler,et al.  Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial , 2018, JAMA oncology.

[21]  James L Mohler,et al.  NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[23]  Anna Veronika Dorogush,et al.  CatBoost: unbiased boosting with categorical features , 2017, NeurIPS.

[24]  Sebastian Thrun,et al.  Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.

[25]  T. Ahlering,et al.  Limitations of the National Comprehensive Cancer Network® (NCCN®) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer , 2017, The Journal of urology.

[26]  Kunwei Shen,et al.  Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[27]  Holger H. Hoos,et al.  Analysing differences between algorithm configurations through ablation , 2015, Journal of Heuristics.

[28]  Jianbo Li,et al.  Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. , 2016, Urology.

[29]  Ni Chen,et al.  The evolving Gleason grading system. , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[30]  F. Saad,et al.  The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements , 2016, Biomarkers in cancer.

[31]  Jian Sun,et al.  Deep Residual Learning for Image Recognition , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).

[32]  H. Sandler,et al.  Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[34]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[35]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[38]  D. Bostwick,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.

[39]  H. Baxter Williams,et al.  A Survey , 1992 .